GLP-1 Medications for Older Adults: What People Over 65 Should Know

*This article is for informational and educational purposes only. It is not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved. Clinical research cited here was conducted using FDA-approved formulations. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

Weight management gets more complicated after 65. The standard advice for younger adults, eat less and move more, still applies, but the physiology underlying it has shifted. Hormonal changes, slower metabolic rate, reduced muscle mass, and multiple coexisting health conditions make obesity in older adults harder to treat and, if untreated, more consequential.

GLP-1 receptor agonists like semaglutide and tirzepatide have changed the treatment landscape for obesity across age groups. But adults over 65 have specific questions that general articles rarely address: Is this class of medication appropriate at my age? What happens to my muscles? How does this interact with my other medications? And does the research actually include people my age?

This guide answers those questions directly, using the published evidence and the practical considerations that matter most for this population.

---

Why Obesity in Older Adults Deserves Special Attention

The relationship between body weight and health looks different in older adults compared to middle-aged adults. At younger ages, excess weight tends to show up in fat that is easier to detect and measure. In older adults, a condition called "sarcopenic obesity" is common: excess fat accumulates alongside significant muscle loss, so a person may not look overweight while carrying metabolically harmful visceral fat.

Obesity in older adults is directly linked to a higher risk of type 2 diabetes, cardiovascular disease, sleep apnea, osteoarthritis, mobility limitations, and fall-related injuries. The functional consequences are often the most immediately impactful. Carrying excess weight strains joints that are already less resilient, reduces cardiovascular fitness that was already declining, and accelerates loss of mobility and independence.

At the same time, older adults metabolize medications differently. Kidney function declines with age (even in people who feel perfectly healthy). Drug interactions become more likely as the number of medications increases. Appetite suppression, one of the core mechanisms of GLP-1 therapy, carries a different risk profile in someone who is already prone to inadequate protein intake.

Understanding these nuances does not mean GLP-1 medications are unsuitable for older adults. It means the approach to using them needs to account for the specific physiology and context of this age group.

---

What the Research Shows for Adults Over 65

The major clinical trials for semaglutide and tirzepatide included participants across a range of ages. The STEP 1 trial, which established the weight loss efficacy of semaglutide 2.4 mg, enrolled adults up to age 75 and showed a mean body weight reduction of 14.9% over 68 weeks in those receiving the medication [1]. While the primary results were not broken down by age group in the main publication, the enrolled population was broadly representative of adults with overweight and obesity who sought treatment.

The SELECT trial, which studied semaglutide's cardiovascular effects in adults with overweight or obesity but without diabetes, enrolled more than 17,600 participants with a mean age of about 61 years. Many participants were in their 60s and 70s. The trial found that semaglutide reduced the risk of major cardiovascular events by 20% compared to placebo, a finding relevant to older adults who often carry elevated cardiovascular risk [2].

For tirzepatide, the SURMOUNT trials enrolled adults across age ranges, including a meaningful portion over 60. Both medications have been studied in real-world settings that reflect older patient populations.

A 2025 review in *Senior Care Pharmacy* specifically examined GLP-1 receptor agonist use for weight management in older adults, describing case series where patients in their 60s and 70s achieved meaningful weight reduction with generally manageable tolerability [4]. A narrative review in *Nutrients* focused on older women specifically and concluded that GLP-1 receptor agonists can be effective for this population while highlighting that muscle and bone preservation require proactive management [5].

The research picture, taken together, suggests that GLP-1 medications offer real benefits for older adults with obesity, but that the approach to using them should account for the physiological differences of this age group rather than simply mirroring how they are used in a 45-year-old.

---

The Muscle Preservation Question

This is the concern most older adults bring to conversations about GLP-1 therapy, and it deserves a direct, honest answer.

GLP-1 medications produce weight loss through a combination of fat loss and lean mass (muscle) loss. In the major trials, approximately 25 to 40% of total weight lost was lean mass rather than fat. This ratio is not dramatically different from what occurs with other forms of caloric restriction, but it matters more in older adults because they are starting from a lower lean mass baseline.

A 2025 review in *Cardiology Reviews* examined lean mass loss in GLP-1 and GIP/GLP-1 therapy and noted that the clinical implications depend significantly on the context: in younger adults who are active and consuming adequate protein, the muscle loss that accompanies GLP-1 use is often manageable. In older adults, who may already be at the threshold of sarcopenia, the same proportional loss carries greater functional consequences [6].

The good news is that this risk is modifiable. Three evidence-based strategies reduce lean mass loss during GLP-1 therapy:

1. Resistance training. Progressive resistance exercise is the most effective intervention for preserving and building muscle mass, at any age. For older adults on GLP-1 therapy, incorporating two to three sessions of resistance training per week can substantially offset the lean mass loss that would otherwise occur. Even modest resistance exercise, bodyweight movements, resistance bands, or light weights, produces measurable benefit.

2. Adequate protein intake. Protein requirements are higher for older adults than commonly assumed. General dietary guidelines recommend 0.8 grams of protein per kilogram of body weight per day, but research in older adults with sarcopenic obesity suggests that 1.2 to 1.6 grams per kilogram is more appropriate when combined with a weight loss intervention. Because GLP-1 medications reduce appetite significantly, intentional attention to protein consumption becomes especially important. Many people find that prioritizing protein-dense foods at the beginning of each meal, when appetite is highest, helps them meet their targets even on reduced overall intake.

3. Gradual dose titration. Starting at a low dose and titrating slowly allows the body more time to adapt and may reduce the severity of appetite suppression in the early weeks. For older adults, this approach also reduces the risk of dehydration and electrolyte imbalance that can accompany rapid changes in eating patterns.

These strategies do not eliminate lean mass loss during caloric restriction, but they meaningfully reduce it. Your healthcare provider can help you build a plan that accounts for your current activity level and dietary patterns.

---

---

Special Considerations for Older Adults

Beyond muscle preservation, several factors deserve attention when older adults consider GLP-1 therapy.

Kidney Function

GLP-1 medications are cleared through the kidneys, and their tolerability is affected by renal function. Adults over 65 commonly have some degree of reduced kidney function, even when they feel healthy, because glomerular filtration rate declines naturally with age. This does not mean GLP-1 medications are contraindicated in people with mild or moderate kidney disease; in fact, semaglutide has shown protective effects on kidney function in some populations. But it does mean that kidney function should be assessed before and periodically during treatment, and that dose adjustments may be appropriate.

Polypharmacy and Drug Interactions

The average adult over 65 takes multiple prescription medications. GLP-1 receptor agonists slow gastric emptying, which affects how quickly other medications are absorbed. This is particularly relevant for medications where timing and consistent absorption matter, such as thyroid hormone replacement, certain blood pressure medications, and diabetes medications. A pharmacist or prescribing provider can review your full medication list for potential interactions before you start treatment.

Blood sugar management requires special attention for older adults who are also taking insulin or sulfonylureas. GLP-1 medications themselves have a very low risk of causing hypoglycemia, but when combined with these other agents, doses may need adjustment to prevent low blood sugar episodes.

Hydration

Nausea, the most common side effect of GLP-1 medications, is more consequential in older adults because it can rapidly lead to dehydration. Dehydration in older adults is associated with confusion, falls, and cardiovascular stress, risks that are low in younger patients but real for this age group. Monitoring fluid intake carefully, especially during the first weeks of treatment and during each dose increase, is more important for adults over 65 than for younger patients.

Bone Health

GLP-1 receptors are expressed on osteoblasts, and some research suggests potential protective effects on bone density. However, when weight loss is rapid and resistance exercise is not part of the plan, bone density can decline along with muscle mass. This is especially relevant for postmenopausal women, who are already at elevated risk for osteoporosis. Dual-energy X-ray absorptiometry (DEXA) scans to monitor bone density may be appropriate for some patients.

Appetite and Nutritional Adequacy

Because GLP-1 medications substantially reduce appetite, older adults face a real risk of inadequate overall nutrition if they are not intentional about food quality. Prioritizing nutrient-dense foods, lean proteins, vegetables, healthy fats, and complex carbohydrates, over calorically dense but nutritionally sparse options becomes more important, not less, when total food volume decreases.

---

Does Weight Loss Help Older Adults Functionally?

One concern that sometimes surfaces about GLP-1 use in older adults is whether losing weight at this age actually improves quality of life, or whether the risks (muscle loss, nutritional compromise) outweigh the benefits.

The available evidence suggests meaningful benefits for most adults with significant obesity. Reductions in joint load translate to less pain with movement and improved physical function. Improvements in sleep apnea lead to better sleep quality and daytime energy. Reductions in cardiovascular risk markers, blood pressure, blood sugar, and lipid levels, reduce the probability of serious cardiovascular events. The SELECT trial, which enrolled a population similar in cardiovascular risk profile to many older adults, showed that semaglutide produced a 20% reduction in major adverse cardiovascular events over roughly 34 months [2].

The two-year data from the STEP 5 trial, which tracked participants for 104 weeks, showed sustained weight loss with continued treatment, suggesting that the benefits are not confined to a short honeymoon period [3]. For older adults who have struggled with weight-related limitations for years, sustained treatment can represent meaningful improvement in daily function.

The key is not whether to use these medications in older adults, but how to use them thoughtfully: with appropriate dose titration, with active attention to nutrition and protein intake, with resistance exercise built into the plan, and with regular monitoring of kidney function, electrolytes, and medication interactions.

---

Talking to Your Healthcare Provider

If you are over 65 and considering GLP-1 therapy, the following topics are worth discussing directly with your provider before starting.

Current kidney function. Ask for a baseline creatinine and estimated GFR if you have not had one recently. This informs dosing decisions and monitoring frequency.

Medication review. Bring a complete list of your current medications, including over-the-counter drugs and supplements. Ask specifically whether any of them have timing-sensitive absorption that could be affected by slower gastric emptying.

Nutrition plan. Ask for a referral to a registered dietitian who has experience working with older adults on weight management programs. Getting protein and micronutrient targets right matters more at 65 than it does at 35.

Exercise plan. Discuss resistance training options appropriate for your current fitness level and any joint or mobility limitations. Many people over 65 can do more than they expect with appropriate programming.

Monitoring schedule. Understand how often your kidney function, electrolytes, and weight will be tracked during treatment. Regular check-ins are more important in this age group than in younger patients.

Dose titration pace. Ask whether a slower titration schedule makes sense for you. The standard titration timelines used in clinical trials were developed for a broad population. Older adults with lower starting body weight, reduced kidney function, or high sensitivity to appetite effects may benefit from spending additional time at lower doses before advancing.

---

The Bottom Line

GLP-1 receptor agonists are not exclusively a treatment for younger adults. The research supports their use across a range of ages, and the benefits they offer, weight reduction, improved cardiovascular risk markers, better sleep, and reduced joint stress, are directly relevant to the health concerns most older adults face.

What changes with age is not the appropriateness of these medications but the care required in using them. Muscle preservation through resistance exercise and adequate protein is not optional in this age group. Monitoring kidney function and managing drug interactions requires more attention. And titrating slowly, to allow the body to adapt and to reduce the risk of dehydration and nutritional inadequacy, matters more than moving quickly toward a target dose.

If you are over 65 and managing obesity, GLP-1 therapy may offer meaningful benefits. A conversation with your healthcare provider, armed with the questions above, is the best place to start.

---

*Compounded semaglutide and tirzepatide are not FDA-approved. Clinical trial data cited in this article was generated using FDA-approved branded formulations; results may differ from compounded versions. This content is educational and does not constitute medical advice. Results vary by individual. Always consult a licensed healthcare provider before making changes to your treatment.*

---

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*. 2023;389(24):2221-2232. [PMID: 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/)

1. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat Med*. 2022;28(10):2083-2091. [PMID: 36216945](https://pubmed.ncbi.nlm.nih.gov/36216945/)

1. Toma L, et al. Geriatric Pharmacotherapy Case Series: GLP-1 Receptor Agonists for Weight Management in Older Adults. *Sr Care Pharm*. 2025. [PMID: 41966038](https://pubmed.ncbi.nlm.nih.gov/41966038/)

1. Moscucci F, et al. A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Bone and Muscle. *Nutrients*. 2025. [PMID: 41754149](https://pubmed.ncbi.nlm.nih.gov/41754149/)

1. Haner Wasserstein D, et al. Lean Mass Loss in Glucagon-Like Peptide-1/GIP Therapy: Clinical Implications for Obesity and Cardiovascular Care. *Cardiol Rev*. 2025. [PMID: 41636548](https://pubmed.ncbi.nlm.nih.gov/41636548/)